Glow Lifetech Reduces Over 41 Million Warrants and 5 Million Options, Strengthening Capital Structure; All $0.05 Warrants Now Expired

Executive Summary

• Glow Lifetech reduced its outstanding share purchase warrants by 41,031,673 and stock options by 5,025,000 during Q1 2026, cutting the fully‑diluted share count by ~16.6% over the trailing twelve months.
• 10,908,302 warrants were exercised, generating $542,415 in proceeds, with ~89% of exercises coming from management, directors and long‑term strategic shareholders.
• The company highlighted that the reduction builds on prior balance‑sheet improvements—including achieving debt‑free status and its first positive cash flow from operations—strengthening its financial foundation for future growth.

Key Details

• Warrant & Option Reduction: 41,031,673 share purchase warrants and 5,025,000 stock options expired unexercised in Q1 2026.
• Expired Warrants: 30,123,371 (76%) of the warrants expired without exercise.
• Exercised Warrants: 10,908,302 warrants were exercised for total proceeds of $542,415.
• Exercise Participation: Approximately 89% of exercised warrants were purchased by management, directors, and long‑term strategic shareholders.
• Impact on Dilution: Fully diluted share count reduced by ~16.6% over the last twelve months due to warrant expiries and option expiries.
• Capital Structure Benefits: Reduction in overhang simplifies equity structure, improves shareholder alignment, and enhances equity quality.
• Financial Milestones Referenced: Debt‑free status (see Nov 11 2025 release) and first positive cash flow from operations (see Nov 25 2025 release).

Notable Quotes

“This significant reduction in our warrant and option overhang marks an important milestone for Glow and reflects our continued focus on disciplined capital and financial management,” – Rob Carducci, CEO
“The participation from management, directors, and long‑term shareholders in warrant exercises further demonstrates strong alignment and confidence in our strategy.” – Rob Carducci, CEO